Biotech Values

[AlpineBV_Miller]

It is important to note that traditionally, bone metastases are not included in response evaluation for solid tumors, as standard response criteria apply only to tumors in other organs (soft tissue disease). Based on those criteria, cabo led to a modest response rate of 6%, with the majority of patients (82%) achieving stable disease as their best response.

This isn't 100% accurate. New bone lesions count as progression under RECIST. Resolution of existing lesions do not count as response under RECIST.